Endpoints News
The latest on UnitedHealth’s AI push Read in browser
Endpoints News
Tuesday, 21 July 2026
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mid-Year Healthcare Venture Trends to Watch
Mid-Year Healthcare Venture Trends to Watch
sponsored by HSBC
Peptide curious
With an FDA advisory committee set to decide this week whether it recommends that several popular peptides be reclassified, I wanted to learn more. Cue a last-minute ticket purchase to a “Peptides 101” event in New York.
To my surprise, over 250 people had signed up. Those of us who made it crammed into the backroom of a West Village bar for a crash course on peptides, including a live demonstration of how to inject them.
The crowd ranged from skeptics to the curious. Some had tried a peptide once or twice, and some took them regularly. In a show of hands, three-fourths of the crowd said they’ve heard of Chinese peptides before. Two-thirds recognized BPC-157, a popular peptide marketed for muscle recovery, while around a quarter said they’ve tried a peptide themselves.
Based on the Q&A, many attendees thought peptides are worth exploring but had lots of questions about the safety and logistics of doing so, like where to buy them, what long-term risks look like and how to approach dosing. 
Peptides, I learned, are cheaper than I thought. The speaker, Julius Ritter, a peptide user himself who founded the California Peptide Club, shared that he spends around $300 a month ordering three types of peptides directly from China. The discount comes with risks, though. Ritter said he has paid but never received the product. Plus, there are potential quality and efficacy issues.
Research on many peptides remains limited. The peptide community relies on physicians knowledgeable about peptides, crowdsourced information and personal anecdotes. Peptides, Ritter said, are not a substitute for fundamentals of health like sleep and exercise, but more of a final, incremental boost. 
If the advisory committee decides to recommend reclassifying some popular peptides this week, potentially making them more widely available, Ritter predicted that the industry could expand beyond injections into consumer products, like peptide-infused foods, following a path similar to that of the marijuana industry. If the crowd clamoring for more information at a bar in NYC was any indication, that could become a booming business.
- Ngai
Here’s what’s new
UnitedHealth Group lays out progress in AI push
Af­ter an­nounc­ing a hefty in­vest­ment in AI ear­li­er this year, Unit­ed­Health laid out how it's us­ing the tech­nol­o­gy across its busi­ness in a quar­ter that land­ed bet­ter than ex­pect­ed.
Inside a NYC peptide meetup
A screenshot of the crowd at the peptides meetup held in NYC
Ngai, and a crowd of New Yorkers, packed the backroom of a bar last week to listen to a talk about peptides. (Photo credit: DeSciNYC)
This week in health Тech
Notetaking startup Nabla hired Brian Manning as its next CEO. Manning succeeds Alex LeBrun, who will serve as executive chairman and chief AI officer. Before Nabla, Manning was an executive at health software company Bamboo Health.
A program testing prior authorizations in fee-for-service Medicare will live on, after Republicans in the Senate voted down a Democrat-led measure that would have ended it. Called WISeR, the program uses AI to approve and deny care for Medicare beneficiaries in six states.
Another veteran Epic executive has left the company, the second this month, Second Opinion reports. AI SVP of research and development Seth Hain, who oversaw the development of Epic’s many AI tools, departed after more than two decades. Epic told us it does not comment on personnel.
Virtual neurodegenerative disease care startup Synapticure is working with Biogen around a program for ataxia. As part of it, Biogen will help spread awareness to the program as well as educational resources for those living with ataxias, a group of conditions associated with changes to movement. 
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin
Worldwide made. Thanks for reading.
Unsubscribe preferences
Unsubscribe from all newsletters
FT Specialist Logo A service from the Financial Times